In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.
Lykos’ MDMA-assisted therapy stumbles at adcomm amid questions about study, safety and abuse
An FDA advisory committee voted against backing Lykos Therapeutics’ MDMA-based therapy for post-traumatic stress disorder, a blow to the biotech company’s efforts to bring the
June 5, 2024